PHAR vs. MLYS, LYEL, ZYME, SVRA, SLN, CALT, GHRS, AVBP, ORIC, and PHAT
Should you be buying Pharming Group stock or one of its competitors? The main competitors of Pharming Group include Mineralys Therapeutics (MLYS), Lyell Immunopharma (LYEL), Zymeworks (ZYME), Savara (SVRA), Silence Therapeutics (SLN), Calliditas Therapeutics AB (publ) (CALT), GH Research (GHRS), ArriVent BioPharma (AVBP), ORIC Pharmaceuticals (ORIC), and Phathom Pharmaceuticals (PHAT). These companies are all part of the "pharmaceutical preparations" industry.
Pharming Group (NASDAQ:PHAR) and Mineralys Therapeutics (NASDAQ:MLYS) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their media sentiment, dividends, analyst recommendations, earnings, community ranking, profitability, valuation, institutional ownership and risk.
Mineralys Therapeutics has a net margin of 0.00% compared to Pharming Group's net margin of -4.01%. Pharming Group's return on equity of -4.61% beat Mineralys Therapeutics' return on equity.
In the previous week, Pharming Group had 7 more articles in the media than Mineralys Therapeutics. MarketBeat recorded 9 mentions for Pharming Group and 2 mentions for Mineralys Therapeutics. Mineralys Therapeutics' average media sentiment score of 0.99 beat Pharming Group's score of 0.92 indicating that Mineralys Therapeutics is being referred to more favorably in the news media.
Pharming Group received 1 more outperform votes than Mineralys Therapeutics when rated by MarketBeat users. However, 100.00% of users gave Mineralys Therapeutics an outperform vote while only 50.00% of users gave Pharming Group an outperform vote.
0.0% of Pharming Group shares are held by institutional investors. Comparatively, 84.5% of Mineralys Therapeutics shares are held by institutional investors. 2.1% of Pharming Group shares are held by insiders. Comparatively, 33.2% of Mineralys Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.
Pharming Group has a beta of 0.2, meaning that its stock price is 80% less volatile than the S&P 500. Comparatively, Mineralys Therapeutics has a beta of 2.05, meaning that its stock price is 105% more volatile than the S&P 500.
Pharming Group currently has a consensus price target of $37.00, suggesting a potential upside of 297.85%. Mineralys Therapeutics has a consensus price target of $33.50, suggesting a potential upside of 157.69%. Given Pharming Group's higher probable upside, research analysts plainly believe Pharming Group is more favorable than Mineralys Therapeutics.
Pharming Group has higher revenue and earnings than Mineralys Therapeutics. Pharming Group is trading at a lower price-to-earnings ratio than Mineralys Therapeutics, indicating that it is currently the more affordable of the two stocks.
Summary
Pharming Group and Mineralys Therapeutics tied by winning 8 of the 16 factors compared between the two stocks.
Get Pharming Group News Delivered to You Automatically
Sign up to receive the latest news and ratings for PHAR and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding PHAR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Pharming Group Competitors List
Related Companies and Tools
